Hypermarcas (OTCMKTS:HYPMY) Trading 4.1% Higher - What's Next?

Key Points

• Hypermarcas' stock price increased by 4.1% during trading on Tuesday, reaching a price of $4.58.
• Analyst ratings for Hypermarcas are optimistic, with Scotiabank issuing a "strong-buy" rating and a consensus rating of "Strong Buy" from market analysts.
• The company reported earnings of $0.12 EPS for the previous quarter, with a net margin of 11.28% and a return on equity of 6.19%.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price traded up 4.1% during trading on Tuesday . The stock traded as high as $4.58 and last traded at $4.58. 1,236 shares changed hands during trading, a decline of 98% from the average session volume of 65,343 shares. The stock had previously closed at $4.40.

Analyst Ratings Changes

Separately, Scotiabank raised shares of Hypermarcas to a "strong-buy" rating in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Hypermarcas currently has a consensus rating of "Strong Buy".

Hypermarcas Trading Down 0.7%

The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of 20.81 and a beta of 0.86. The business has a fifty day simple moving average of $4.40 and a 200 day simple moving average of $4.25.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.12 EPS for the quarter. Hypermarcas had a net margin of 11.28% and a return on equity of 6.19%.

Hypermarcas Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.